MCK
McKesson Corporation NYSE$807.85
Mkt Cap $99.0B
52w Low $637.00
47.2% of range
52w High $999.00
50d MA $893.57
200d MA $812.76
P/E (TTM)
31.5x
EV/EBITDA
16.7x
P/B
—
Debt/Equity
-3.6x
ROE
-277.5%
P/FCF
16.4x
RSI (14)
—
ATR (14)
—
Beta
0.42
50d MA
$893.57
200d MA
$812.76
Avg Volume
801.9K
About
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related product…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | AMC | 9.17 | 9.34 | +1.9% | 822.00 | +4.9% | +16.5% | +15.4% | +17.1% | +13.8% | +16.0% | +11.8% | — |
| Nov 5, 2025 | AMC | 9.03 | 9.86 | +9.2% | 844.26 | -1.4% | +1.7% | +0.9% | +1.8% | +1.4% | -0.4% | -4.2% | — |
| Aug 6, 2025 | AMC | 8.14 | 8.26 | +1.5% | 703.76 | -2.9% | -5.8% | -5.0% | -4.4% | -6.4% | -5.8% | -2.3% | — |
| May 8, 2025 | AMC | 9.83 | 10.12 | +3.0% | 690.25 | +3.2% | +0.5% | -0.4% | -0.4% | -1.2% | +2.4% | +2.6% | — |
| Feb 5, 2025 | AMC | 8.60 | 8.03 | -6.6% | 606.90 | -2.8% | -1.2% | -1.8% | -0.6% | +0.6% | -2.0% | +6.1% | — |
| Nov 6, 2024 | AMC | 6.88 | 7.07 | +2.8% | 549.31 | +10.4% | +10.6% | +11.6% | +12.1% | +12.4% | +13.7% | +9.9% | — |
| Aug 7, 2024 | AMC | 7.21 | 7.88 | +9.3% | 617.51 | -7.1% | -11.3% | -12.4% | -10.8% | -10.6% | -10.5% | -18.4% | — |
| May 7, 2024 | AMC | 6.34 | 6.18 | -2.5% | 545.75 | +1.2% | -0.4% | +1.7% | +2.6% | +1.6% | +1.1% | +7.4% | — |
| Feb 7, 2024 | AMC | 7.04 | 7.74 | +9.9% | 516.98 | -2.3% | -4.4% | -3.0% | -4.4% | -2.4% | -3.1% | +2.0% | — |
| Nov 1, 2023 | AMC | 6.15 | 6.23 | +1.3% | 459.59 | -4.0% | -2.6% | -1.5% | +0.1% | -0.3% | +0.2% | +1.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | William Blair | Initiates | Outperform | — | $828.32 | $836.33 | +1.0% | +0.8% | -0.7% | -1.6% | -1.7% | — |
| Apr 22 | UBS | Maintains | Buy → Buy | — | $842.25 | $840.77 | -0.2% | -1.5% | -0.7% | -1.7% | -1.7% | -0.9% |
| Apr 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $856.62 | $859.29 | +0.3% | +1.7% | +2.0% | +1.0% | +0.9% | +0.7% |
| Apr 6 | BofA Securities | Maintains | Buy → Buy | — | $884.28 | $862.15 | -2.5% | -3.1% | -3.1% | -1.5% | -1.2% | -2.1% |
| Feb 18 | Barclays | Maintains | Overweight → Overweight | — | $946.47 | $947.43 | +0.1% | +0.1% | -1.0% | +0.1% | +0.3% | +1.2% |
| Feb 10 | JP Morgan | Maintains | Overweight → Overweight | — | $962.32 | $965.00 | +0.3% | -2.8% | -0.9% | -4.8% | -2.9% | -1.6% |
| Feb 5 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $822.00 | $862.00 | +4.9% | +16.5% | +15.4% | +17.1% | +13.8% | +16.0% |
| Feb 5 | Mizuho | Maintains | Neutral → Neutral | — | $822.00 | $862.00 | +4.9% | +16.5% | +15.4% | +17.1% | +13.8% | +16.0% |
| Feb 5 | TD Cowen | Maintains | Buy → Buy | — | $822.00 | $862.00 | +4.9% | +16.5% | +15.4% | +17.1% | +13.8% | +16.0% |
| Nov 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $851.99 | $842.91 | -1.1% | +0.9% | +0.5% | -1.3% | -0.7% | -1.2% |
Recent Filings
8-K · 1.01
! Medium
McKesson Corporation -- 8-K 1.01: Financing / Debt Agreement
McKesson Corporation secured a $1.0 billion credit agreement, providing additional liquidity to support operations and potential strategic initiatives.
Apr 28
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
McKesson's new secured credit facility with leverage-based commitment fees ties borrowing costs to financial performance, incentivizing deleveraging while providing operational flexibility that investors should monitor for debt management efficiency.
Apr 6
8-K · 7.01
! Medium
McKesson Corporation -- 8-K 7.01: Regulation FD Disclosure
McKesson's Regulation FD disclosure of material information to investors signals potential guidance updates or strategic announcements that could significantly impact stock valuation and market expectations.
Mar 6
8-K · 5.02
!!! Very High
McKesson Corporation -- 8-K 5.02: Executive Change
McKesson's CFO Britt Vitalone is retiring effective March 3, 2026, creating a leadership transition that investors should monitor for potential interim management changes and strategic implications.
Mar 5
8-K
McKesson Corporation -- 8-K Filing
McKesson's third quarter revenues grew 11% to $106.2 billion while diluted earnings per share surged 34% to $9.59, demonstrating strong operational performance and margin expansion.
Feb 4
Data updated apr 26, 2026 11:30am
· Source: massive.com